Generation of Pancreatic â Cells from Peripheral Blood Mononucleocytes-Derived-Induced Pluripotent Stem Cells
Since the first generation of induced pluripotent stem cells (iPSCs), many efforts have been made to use them for cell therapies targeting diabetes. The primary focus in the research field was the generation of insulinproducing cells similar to innate ß-cells from human iPSCs. ß-cells play a signifi...
Saved in:
Published in | Journal of stem cells Vol. 14; no. 1; pp. 13 - 20 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hauppauge
Nova Science Publishers, Inc
01.01.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Since the first generation of induced pluripotent stem cells (iPSCs), many efforts have been made to use them for cell therapies targeting diabetes. The primary focus in the research field was the generation of insulinproducing cells similar to innate ß-cells from human iPSCs. ß-cells play a significant role in the pathogenesis of both types of diabetes. In this work, we aimed at generating iPSCs from peripheral blood and their further differentiation into ß-cells. First, we isolated mononuclear cells from peripheral blood and reprogrammed them into iPSCs. After assessments of pluripotency via immunohistochemistry, the generated cells were differentiated into ß-cells. Successful differentiation was confirmed by analyzing cell surface markers specific to ß-cells; CD142, and CD200. Moreover, the expression of PDX1, Insulin, and C-Peptide was detected via immunohistochemistry. Furthermore, the expression levels of ß- cells specific genes; PDX1, Insulin, GATA4, and HNF6 were evaluated by qRT-PCR. Results confirmed the successful generation of iPSCs and their differentiation into ß-cells. In conclusion, iPSCs can provide a promising source of autologous cells that could be considered as a potential cell therapy of diabetes. |
---|---|
ISSN: | 1556-8539 |